Table 1.
Baseline Characteristics
| Study 2 | ||||||
|---|---|---|---|---|---|---|
| Study 1 | No Exercise + Placebo | No Exercise + Tocilizumab | Exercise + Placebo | Exercise + Tocilizumab | Study 3 | |
| Male/female (n) | 5/0 | 1/11 | 5/8 | 3/11 | 3/10 | 10/0 |
| Age (years) | 21 (2) | 48 (12) | 44 (12) | 39 (13) | 44 (12) | 24 (1) |
| Body weight (kg) | 75 (4) | 95 (20) | 99 (17) | 92 (14) | 96 (15) | 84 (6) |
| Body mass index (kg/m2) | 22.3 (0.9) | 33.0 (6.3) | 32.9 (4.9) | 33.0 (4.9) | 33.0 (4.7) | 24.1 (2.1) |
| Bone mineral density (g/cm2) | 1.271 (0.06) | 1.273 (0.082) | 1.260 (0.063) | 1.250 (0.088) | 1.257 (0.080) | - |
| Whole body lean mass (kg) | 66.5 (4.3) | 47.4 (9.1) | 52.7 (11.1) | 45.4 (7.3) | 49.9 (8.1) | 66.7 (4.7) |
| VO2 max (mL/min/kg) | 56 (4) | 27 (5) | 29 (5) | 28 (5) | 29 (6) | 50 (5) |
| HbA1c (mmol/mol) | 34.0 (1.9) | 36.5 (3.8) | 37.2 (2.7) | 33.6 (3.0) | 34.0 (3.0) | 32.8 (2.5) |
| CRP (mg/L) | 1.20 (0.45) | 3.59 (3.09) | 2.01 (1.53) | 3.46 (3.51) | 2.50 (2.57) | <1 |
| Calcium (mmol/L) | 2.34 (0.11) | 2.28 (0.07) | 2.29 (0.08) | 2.29 (0.07) | 2.40 (0.35) | 2.31 (0.08) |
| Phosphate (mmol/L) | 0.85 (0.11) | — | — | — | — | 0.99 (0.11) |
Data are presented as mean (standard deviation).
Abbreviations: CRP = C-reactive protein. HbA1c = hemoglobin A1c.